To evaluate the potential of SET inhibition for treatment of prostate cancer driven by oncogenic PI3K-Akt signaling, we tested the therapeutic effects of OP449 in treatment of an established Pten−/− murine prostate cancer (CaP8) cell line25. The gene discussed is AKT1; the disease is prostate cancer.